Abstract
Objectives
N6‐methyladenosine (m6A) is one of the most abundant internal RNA modifications. We investigated the role of m6A‐modified circRERE in osteoarthritis (OA) and its mechanism.
Materials and Methods
CircRERE and IRF2BPL were screened by microarrays. The role of m6A‐modification in circRERE was examined by methylated RNA precipitation and morpholino oligo (MOs) treatment. The axis of circRERE/miR‐195‐5p/IRF2BPL/β‐catenin was determined using flow cytometry, western blotting and immunofluorescence in human chondrocytes (HCs) and corroborated using a mouse model of destabilization of medial meniscus (DMM) with intra‐articular (IA) injection of adeno‐associated viruses (AAV).
Results
CircRERE was decreased in OA cartilage and chondrocytes compared with control. CircRERE downregulation was likely attributed to its increased m6A modification prone to endoribonucleolytic cleavage by YTHDF2‐HRSP12‐RNase P/MRP in OA chondrocytes. MOs transfection targeting HRSP12 binding motifs in circRERE partially reversed decreased circRERE expression and increased apoptosis in HCs treated with IL‐1β for 6 h. CircRERE exerted chondroprotective effects by targeting miR‐195‐5p/IRF2BPL, thus regulating the ubiquitination and degradation of β‐catenin. CircRere (mouse homologue) overexpression by IA‐injection of AAV‐circRere into mice attenuated the severity of DMM‐induced OA, whereas AAV‐miR‐195a‐5p or AAV‐sh‐Irf2bpl reduced the protective effects. The detrimental effects of AAV‐sh‐Irf2bpl on DMM‐induced OA were substantially counteracted by ICG‐001, an inhibitor of β‐catenin.
Conclusions
Our study is a proof‐of‐concept demonstration for targeting m6A‐modified circRERE and its target miR‐195‐5p/IRF2BPL/β‐catenin as potential therapeutic strategies for OA treatment.
Liu et al. demonstrate that circRERE expression is downregulated in human osteoarthritis (OA) cartilage and chondrocytes, and circRERE downregulation is likely attributed to its increased m6A modification prone to endoribonucleolytic cleavage by YTHDF2‐HRSP12‐RNase P/MRP. Mechanistically, circRERE downregulation leads to aberrant β‐catenin ubiquitin and degradation by targeting miR‐195‐5p/IRF2BPL during OA pathogenesis.
1. INTRODUCTION
Osteoarthritis (OA) is a common debilitating joint disease characterized by cartilage destruction, synovial inflammation, and bone remodelling in the form of subchondral bone thickening and osteophyte formation, eventually leading to chronic joint pain and disability. 1 , 2 The risk factors for OA include age, obesity, injury, and genetics. 3 OA pathogenesis is complicated and multifactorial involving inflammation, cellular senescence, mitochondrial dysfunction, aberrant epigenetic regulation, and alterations in signalling pathways, such as Wnt/β‐catenin. 4 , 5 , 6 OA represents a significant source of morbidity and socioeconomic burden as aging and obese populations are increasing worldwide. 7 , 8 The current pharmaceutical treatment for OA mainly refers to symptomatic relief rather than stopping or delaying its progression. 9 Despite the progressive development of OA diagnosis using imaging equipment or biochemical markers, it is difficult to detect early‐stage OA since the key genes and molecular mechanisms are unclear. Therefore, there is an urgent need to decipher the pathogenesis of OA and identify effective targets. 10 , 11 , 12
Circular RNAs (circRNAs) are novel endogenous noncoding RNAs (ncRNAs) generated via alternative back‐splicing. They are much more stable than linear mRNAs due to their covalently closed loop configuration without a free 3' or 5' end. 13 They play important roles in biological processes such as apoptosis, proliferation, and differentiation, and are involved in various human diseases, including the pathogenesis of OA. 14 , 15 , 16 Nevertheless, the pathophysiologic role of circRNAs in OA remains largely unexplored. Moreover, some circRNAs are aberrantly expressed in OA cartilage, the mechanism of which remains poorly investigated.
N6‐methyladenosine (m6A) is a prevalent reversible RNA methylation associated with mRNAs and ncRNAs with the RRACH (R = G or A; H = A, C, or U) consensus sequence preferentially occurring around stop codons, within long exons and at 3' untranslated regions (3' UTRs). 17 , 18 M6A regulates their splicing, translation, export, and stability. 19 The methylation is added and removed by methyltransferase (‘writers’) such as METTL3 and METTL14, and demethylase (‘erasers’) such as FTO and ALKBH5, respectively. 20 , 21 The downstream biological effects of m6A modification mainly depends on the specific binding of m6A readers such as YTH domain‐containing proteins (YTHDFs). 18 M6A modification regulates gene expression, cell fate and involves the pathogenesis of many human diseases, including cancers, nervous system diseases, heart failure, and diabetes. 22 , 23 , 24 , 25 Notably, m6A‐modified circRNAs are endoribonuclease‐cleaved by the YTHDF2‐HRSP12‐RNase P/MRP axis. 26 However, the role of m6A modification in the occurrence and development of OA remains largely unknown, although studies indicated the involvement of METTL3. 27 , 28 And the functions of m6A‐containing circRNAs in OA need to be explored.
Interferon Regulatory Factor 2 Binding Protein Like (IRF2BPL) is an E3 ubiquitin protein ligase which has been shown to drive ubiquitination and degradation of β‐catenin, thus probably inhibiting Wnt/β‐catenin signalling. IRF2BPL belongs to the IRF2BP family, which also includes IRF2BP1, IRF2BP2. 29 , 30 Increased β‐catenin expression is observed in OA cartilage inducing hypertrophic differentiation of chondrocytes. 31 Wnt/β‐catenin signalling is activated during OA pathological process and inhibition of Wnt/β‐catenin signalling in mice exhibits disease‐modifying effects on DMM‐induced OA. 32 Balanced regulation of Wnt/β‐catenin signalling in chondrocytes is essential for cartilage homeostasis. 9 But the upstream mechanism by which Wnt/β‐catenin signalling is regulated during the pathogenesis of OA still remains largely unknown. CircRNA participates in the regulation of β‐catenin signalling in cancers, such as papillary thyroid cancer and hepatocellular carcinoma. 33 , 34 However, up to date, it remains unclear whether there is a functional link between circRNA and β‐catenin signalling in OA.
Here, using circRERE as an example, we highlighted the role of m6A‐modified circRNA in OA. We found that circRERE was down‐regulated in human OA cartilage and chondrocytes. In vitro and in vivo experiments revealed the chondro‐protective roles of circRERE in OA. What's more, circRERE downregulation in human OA chondrocytes is likely attributed to its increased m6A modification prone to endoribonucleolytic cleavage by YTHDF2‐HRSP12‐RNase P/MRP.
2. EXPERIMENTAL PROCEDURES
Experimental procedures are described in the supplementary materials and methods.
3. RESULTS
3.1. Decreased expression of circRERE/circRere in OA cartilage
The potential roles of circRNAs in OA were initially investigated using circRNA microarray of cartilage from OA patients (n = 4) and amputees without OA (n = 4) (GEO accession: GSE178724). The heat map showed 298 differentially expressed circRNAs by at least 2.0‐fold (p < 0.05) (Figure 1A), and the variation in expression was shown in scatter and volcano plots (Figure 1B,C). Figure 1D showed the steps for identification of circRERE. Representative histomorphological staining of human damaged and intact OA cartilage and control cartilage was shown in Figure 1E. Thirteen conserved downregulated circRNAs (at least 3.0‐fold, p < 0.05) were identified between humans and mice using the circbank database. 35 Five circRNAs were non‐specifically amplified (circFMN2, circTLK1, circDENND1A, circSMARCB1, circRNF114), three were undetected (circLDLRAD4, circRMDN2, circFRAS1), and five were further detected between human OA and control cartilage using quantitative RT‐PCR (qRT‐PCR) (n = 20) (Figure S1A, B). QRT‐PCR showed that the expression levels of CircZFHX4, circTBCK, circARHGAP5 and circRERE significantly decreased in OA cartilage compared with control, with no significant difference in circTENM3. Because circRERE had the greatest difference in expression, its transcription was confirmed in the validation set (n = 40) (Figure 1F), and the differential expression was confirmed by fluorescence in situ hybridization (FISH) (Figure 1G), but differential RERE expression was not observed (Figure S1B). Thus, circRERE was selected for further study. The spliced mature circRERE sequence (434 bp) was derived from exons 5–8 of the gene RERE (Figure 1H,I). CircRERE was more stable than linear RERE determined by RNase R digestion and actinomycin D treatment (Figure 1J,K). FISH of human chondrocytes showed that circRERE was predominantly located in the cytoplasm and decreased in OA chondrocytes compared with control (Figure 1L). Downregulated circRERE was also found in IL‐1β‐treated HCs in a time‐dependent manner (Figure 1M). Furthermore, downregulated circRERE expression was observed in damaged OA cartilage compared with intact cartilage from the same patient (n = 60) (Figure 1N). The mouse homologue, circRere was also examined due to the conservation of circRERE between humans and mice (Figure S1C). Decreased circRere expression was observed in the cartilage of mice subjected to the surgery of destabilization of medial meniscus (DMM) compared with that of sham group (Figure 1O). Circularisation, stability, and location of circRere were validated in mouse chondrocytes (MCs) (Figure 1P and Figure S1D‐F). These results indicated that circRERE/circRere may exert disease‐specific effects in the pathogenesis of OA.
3.2. Overexpression of circRERE (circRere) ameliorated osteoarthritis in vitro (in vivo)
For circRERE interference, three different siRNAs were designed and tested in HCs (Figure 2A). The role of circRERE in OA in vitro was examined by circRERE downregulation or overexpression in HCs using adenovirus expressing shRNA#1 against circRERE (Ad‐sh‐circRERE) or adenovirus overexpressing circRERE (Ad‐circRERE). RERE expression was unaffected by circRERE downregulation or overexpression (Figure 2B,C). CircRERE silencing increased apoptotic HCs and affected the protein levels of MMP13, ADAMTS5, COL2A1 and Aggrecan, whereas its overexpression reversed IL‐1β‐induced apoptosis of HCs (Figure 2D‐F). In addition, the chondroprotective effect of circRERE overexpression on HCs stimulated with IL‐1β was supported by immunofluorescence (IF) and EdU assays (Figure 2G,H). However, this effect was unseen by senescence‐associated‐β‐galactosidase (β‐gal) staining (Figure S2A).
Due to the conservation of circRERE and circRere between humans and mice, the role of circRere in OA progression in vivo was investigated using the surgery of DMM on 10‐week‐old male C57BL/6 mice and AAV infection. An AAV system has been demonstrated to effectively deliver target genes to cartilage and other joint tissues. 36 , 37 GFP‐tagged AAV‐circRere or AAV‐vector was intra‐articular (IA) injected into the affected knees of DMM mice (commencing 1 week after DMM surgery) (Figure S2B). Infected efficiency was determined by fluorescence examination of knee sections and qRT‐PCR of cartilage (Figure 2I and Figure S2C). DMM + AAV‐circRere group exhibited reductions in the examined manifestations of OA compared with DMM + AAV‐vector group 8 weeks after DMM, including cartilage destruction, subchondral bone plate (SBP) thickening and pain, but not synovitis and osteophyte formation (Figure 2J,L). In addition, immunohistochemical (IHC) staining and TUNEL assay showed that the DMM‐induced upregulation of MMP13 proteins, downregulation of COL2A1 proteins and upregulation of apoptotic chondrocytes in damaged mouse cartilage were significantly diminished in DMM + AAV‐circRere group (Figure 2K,L), which further revealed the chondroprotective effects of circRere in vivo. These results indicated that circRERE/circRere had important roles in pathophysiologic process of OA.
3.3. M6A‐modification of circRERE modulated its expression and function in OA chondrocytes
Next, the mechanism underlying circRERE downregulation in OA chondrocytes was explored. M6A not only regulates the generation, transport, stability and degradation of targeted genes (such as mRNA, circRNA), but also influences the corresponding biological function and processes by affecting the targeted gene expression. 38 , 39 Particularly, m6A‐modified circRNAs are reported to be endoribonuclease‐cleaved by the axis of YTHDF2‐HRSP12‐RNase P/MRP. 26
To investigate the effects of m6A modification on circRERE expression or function, we first examined whether circRERE contains m6A methylation, m6A‐specific immunoprecipitation (MeRIP) assays and subsequent qRT‐PCR analysis using divergent primers showed that circRERE was enriched in m6A antibody‐precipitated complexes (Figure 3A,B). RNA pulldown assays revealed that circRERE interacted with several m6A modifiers: METTL3, FTO, and YTHDF2 (Figure 3C). Thus, we hypothesized that m6A‐containing circRERE was subjected to endoribonucleolytic cleavage by YTHDF2‐HRSP12‐RNase P/MRP. Downregulation of YTHDF2, HRSP12, or POP1 in HCs increased the abundance of circRERE, which confirmed above hypothesis (Figure 3D). Furthermore, the percentage of m6A‐modified circRERE was upregulated in human OA chondrocytes compared with control observed by MeRIP assays and IF (m6A)‐FISH (circRERE) staining (Figure 3E,F). Above results indicate the possibility that increased m6A modification of circRERE in OA chondrocytes enhances its endoribonucleolytic degradation by YTHDF2‐HRSP12‐RNase P/MRP, and this was supported by the following experiments.
IF (m6A)‐FISH (circRERE) staining and qRT‐PCR assays suggested that decreased circRERE expression in response to IL‐1β stimulation was partly abrogated by the downregulation of YTHDF2 in HCs (Figure 3G,H). Given the evidence that m6A‐containing circRNAs which are associated with YTHDF2 in a pattern of HRSP12‐dependence are preferentially subjected to endoribonucleolytic cleavage by RNase P/MRP. 26 Here, Figure 3I showed the observed enrichment of YTHDF2 with circRERE was obviously reversed by HRSP12 downregulation. Thus, morpholino oligos (MOs) targeting two HRSP12‐binding motifs (GGUUC) in circRERE (MOs‐circRERE) were designed by browsing its sequence. 40 , 41 Transfection with MOs‐circRERE partially reversed the decreased expression of circRERE in HCs stimulated with IL‐1β for 6 h, but not 12 or 36 h (Figure 3J). Notably, flow cytometry (FCM) assay showed that increased apoptosis of HCs upon 6 h IL‐1β treatment was partly rescued by transfection with MOs‐circRERE (Figure 3K). Conserved mouse circRere also contains m6A methylation (Figure 3L,M), and the percentage of m6A‐modified circRere was upregulated in IL‐1β‐treated MCs compared with control (Figure 3N). And decreased circRere expression in response to IL‐1β stimulation was partly rescued by the downregulation of Ythdf2 in MCs (Figure 3O). Together, all results suggested that increased m6A modification of circRERE in OA chondrocytes, through recognition by YTHDF2‐HRSP12‐RNase P/MRP, modulated its degradation and function.
3.4. Restoration of circRERE expression alleviated OA by targeting miR‐195‐5p
The cytoplasmic localization of circRERE indicated its potential molecular mechanism in regulating OA may be microRNA (miRNA) sponging, peptide encoding, or circRNA‐protein interactions. 42 The Circular RNA Interactome database predicted that AGO2, IGF2BP3, FMRP, EIF4A3, and DGCR8 binds to circRERE (Figure S4A). 43 RIP assays showed that circRERE interacted with AGO2, FMRP, and IGF2BP3, with AGO2 being the most abundant (Figure 4A and Figure S4B). Therefore, we focused on the ability of circRERE to function as a competing endogenous RNA (ceRNA). 44 , 45 , 46
CircRERE may bind miR‐16‐5p, miR‐424‐5p, miR‐15a‐5p, miR‐15b‐5p, and miR‐195‐5p according to the overlapping predictions of miRanda, TargetScan, and Arraystar's proprietary program predicted miRNA (Figure S4C). RNA pull‐down and qRT‐PCR assays showed that miR‐195‐5p was abundantly pulled down by circRERE in HCs (Figure 4B). The direct interaction between circRERE and miR‐195‐5p was confirmed since the biotinylated wild‐type miR‐195‐5p mimics captured more circRERE compared to mutant miR‐195‐5p in circRERE‐overexpressing HCs (Figure 4C). Furthermore, luciferase reporter assays confirmed the binding of circRERE to miR‐195‐5p (Figure 4D and Figure S4F). FISH revealed the co‐localization of circRERE/circRere and miR‐195‐5p in HCs/MCs (Figure 4E). Therefore, miR‐195‐5p was chosen for further study. QRT‐PCR indicated that miR‐195‐5p expression was higher in OA cartilage than in control (n = 20 for human, n = 10 for mice) (Figure 4F). Differential expression of circRERE and miR‐195‐5p were confirmed in human OA and control cartilage by FISH (Figure 4G).
The functions of miR‐195‐5p in vitro were investigated using FCM, EdU, and IF assays. Loss‐of‐function experiments suggested that downregulation of miR‐195‐5p in HCs rescued IL‐1β‐induced apoptosis and aberrant expression of anabolic and catabolic molecules (Figure 4I,J), but did not affect proliferation (Figure S4J,K). The effect of miR‐195‐5p overexpression or downregulation on the protein levels of MMP13, ADAMTS5 and COL2A1 in HCs was confirmed by western blotting (WB) (Figure 4H and Figure S4I). Furthermore, increased apoptosis of HCs in miR‐195‐5p overexpression group was counteracted by circRERE overexpression (Figure 4K), indicating that circRERE is involved in OA by sponging miR‐195‐5p. This mechanism was supported by WB (Figure 4L and Figure S4L).
Considering that circRERE is conserved between humans and mice, and nucleotides upstream and downstream of the miR‐195‐5p target sequences in circRERE and circRere were also highly conserved (Figure S4D,E). We further investigated whether circRere is involved in OA in mice by targeting miR‐195a‐5p. GFP‐tagged AAV‐circRere and AAV‐miR‐195a‐5p were co‐IA‐injected into the operated knees in DMM mice (commencing 1 week after DMM surgery) as Figure S2B and the infected efficiency was confirmed by fluorescence examination of knee sections and qRT‐PCR analysis of cartilage (Figure 4M and Figure S4M).
Marked increases in the examined manifestations of DMM‐induced OA were observed in the DMM + AAV‐miR‐NC and DMM + AAV‐circRere + AAV‐miR‐195a‐5p groups compared with the Sham+AAV‐miR‐NC and DMM + AAV‐circRere + AAV‐miR‐NC groups, including cartilage erosion, SBP thickness and pain, but not synovitis and osteophyte maturation (Figure 4N,P), indicating that the protective effects of AAV‐circRere on DMM‐induced OA were counteracted by AAV‐miR‐195a‐5p overexpression in mice. Furthermore, IHC staining for MMP13 and COL2A1 and TUNEL assays in mouse cartilage of four groups were consistent with above results of Safranin O‐fast green and HE staining and Von Frey assays (Figure 4O,P).
3.5. CircRERE modulated β‐catenin ubiquitination and degradation by targeting miR‐195‐5p/IRF2BPL in human chondrocytes
We then investigated the ability of circRERE to exert a chondroprotective role by modulating expression of miR‐195‐5p targeting genes. An mRNA microarray (GEO accession: GSE178557) was performed using the same cartilage samples as the aforementioned circRNA microarray (at least 2.0‐fold, p < 0.05, Figure 5A and Figure S5A,B). And Gene Ontology (GO) analysis revealed that downregulated mRNAs in OA cartilage were involved in extracellular matrix structural constituent (GO:0005201) and extracellular matrix (GO:0031012), and upregulated mRNAs in OA cartilage were enriched in cell death (GO:0008219), cellular catabolic process (GO:0044248), programmed cell death (GO:0012501), and apoptotic process (GO:0006915) (Figure S5C‐H). Integration of mRNA microarray data and predictions using PITA, miRanda, Pictar, and TargetScan indicated nine possible targets of miR‐195‐5p (Figure S5K). QRT‐PCR suggested that interferon regulatory factor 2 binding protein like (IRF2BPL) was modulated by circRERE silencing (Figure S5L). IF (IRF2BPL)‐FISH (circRERE) staining confirmed that downregulation of circRERE decreased IRF2BPL protein levels in HCs (Figure 5B). The TargetScan database also showed the conservation of miR‐195‐5p and its target IRF2BPL gene in humans and mice (Figure S5M). Luciferase reporter assays showed that miR‐195‐5p overexpression decreased the luciferase activity of WT IRF2BPL 3'‐UTR, but not the mutant (Figure 5C and Figure S5N). Furthermore, WB revealed that transfection with miR‐195‐5p mimics downregulated IRF2BPL protein levels in HCs, whereas miR‐195‐5p inhibitor displayed the opposite effect (Figure 5D). IF staining and qRT‐PCR showed that IRF2BPL expression was significantly downregulated in OA cartilage from humans and mice (Figure 5E,F and Figure S5O), and the downregulated expression of Irf2bpl was also observed in IL‐1β stimulated MCs (Figure 5G), indicating its potential roles in OA pathogenesis. Therefore, IRF2BPL was selected for further analyses. IRF2BPL downregulation affected the expression of anabolic and catabolic molecules in HCs (Figure 5H). In addition, rescue experiments suggested that IRF2BPL overexpression abolished miR‐195‐5p overexpression‐ or circRERE knockdown‐induced apoptosis and aberrant MMP13 and COL2A1 expression in HCs (Figure 5I‐L). Hence, circRERE exerted chondroprotective effects by modulating the expression of miR‐195‐5p targeting IRF2BPL.
IRF2BPL is an E3 ubiquitin protein ligase which can drive proteasome‐mediated ubiquitin‐dependent degradation of β‐catenin, and β‐catenin expression increases proportionally with OA severity. 30 , 31 Thus, we studied if the chondro‐regulatory mechanism of circRERE‐miR‐195‐5p‐IRF2BPL axis was mediated by the role of IRF2BPL in β‐catenin ubiquitination and degradation. First, overexpression of IRF2BPL in HCs did not affect β‐catenin mRNA expression (Figure 5M), but markedly decreased β‐catenin protein level (Figure 5N). Co‐immunoprecipitation (IP) in HCs revealed an interaction between IRF2BPL and β‐catenin (Figure 5O). Second, endogenous β‐catenin ubiquitination in HCs increased and decreased during IRF2BPL overexpression and knockdown, respectively (Figure 5P). Third, there was downregulated expression and suppressed activation of β‐catenin in HCs overexpressing circRERE, whereas the effects were abrogated after IRF2BPL knockdown. Similarly, the effects of miR‐195‐5p overexpression on β‐catenin expression and activation were counteracted by IRF2BPL overexpression (Figure 5Q and Figure S5P,Q). Fourth, the chondro‐destructive effects of circRERE downregulation on HCs were diminished by ICG‐001, a small molecule that antagonizes TCF/β‐catenin‐mediated transcription, 47 determined by FCM and IF assays of HCs (Figure 5R,S). Collectively, our data indicated that circRERE participated in pathophysiologic process of OA by targeting miR‐195‐5p/IRF2BPL to regulate β‐catenin ubiquitination and degradation.
3.6. CircRere targets miR‐195a‐5p/Irf2bpl/β‐catenin to participate in the pathophysiologic process of mouse OA in vivo
Considering the conservation of circRERE/miR‐195‐5p/IRF2BPL axis in humans and mice, the role of circRere/miR‐195a‐5p/Irf2bpl/β‐catenin axis in OA was further tested in vivo by performing DMM surgery on mice and co‐IA injection with corresponding AAVs (or antagonist). For deprivation experiments, AAV‐circRere and AAV‐sh‐Irf2bpl were co‐IA injected into the affected knees (commencing 1 week after DMM surgery). Infected efficiency was determined by fluorescence examination of knee sections and qRT‐PCR of cartilage (Figure 6A and Figure S6A).
Marked increases in the examined manifestations of DMM‐induced OA were observed in the DMM + AAV‐shRNA‐NC and DMM + AAV‐circRere + AAV‐sh‐Irf2bpl groups compared with the Sham + AAV‐shRNA‐NC and DMM + AAV‐circRere+AAV‐shRNA‐NC groups, including cartilage erosion, SBP thickness and pain, but not synovitis and osteophyte maturation (Figure 6B,D and Figure S6B), indicating that the protective effects of AAV‐circRere on OA progression caused by DMM in mice were counteracted by AAV‐sh‐Irf2bpl. In addition, IHC staining for MMP13 and COL2A1 and TUNEL assays in mouse cartilage of four groups were consistent with the above results. Particularly, the β‐catenin levels in mouse cartilage were increased in the DMM + AAV‐shRNA‐NC and DMM + AAV‐circRere + AAV‐sh‐Irf2bpl groups compared with the Sham + AAV‐shRNA‐NC and DMM + AAV‐circRere + AAV‐shRNA‐NC groups (Figure 6C,D), indicating that circRere modulated the progression of DMM‐induced OA in mouse by targeting β‐catenin.
For the rescue experiments, AAV‐sh‐Irf2bpl (commencing 1 week after DMM surgery) and ICG‐001 (commencing 1 week after DMM surgery, once weekly for 7 weeks) were co‐IA injected into the affected knees. Infected efficiency was determined by fluorescence examination of knee sections and qRT‐PCR of cartilage (Figure S6C,D). Significant reductions in the examined manifestations of DMM‐induced OA were observed in DMM + AAV‐sh‐Irf2bpl + ICG‐001 group compared with DMM + AAV‐sh‐Irf2bpl + vehicle group, including cartilage erosion, synovitis, SBP thickness and pain, but not osteophyte maturation (Figure 6E,G and Figure S6E), indicating that IA injection of ICG‐001 for 7 weeks significantly abolished the detrimental effects of AAV‐sh‐Irf2bpl on the progression of DMM‐induced OA, which was consistent with a previous report to a certain extent. 47 Expression of MMP13, COL2A1 and β‐catenin and TUNEL assays in mouse cartilage of four groups also corroborated above results (Figure 6F,G). Taken together, these results suggest that circRere is involved in the pathogenesis of DMM‐induced OA in mice by targeting miR‐195a‐5p/Irf2bpl/β‐catenin, and the schematic for the article is shown (Figure 6H).
4. DISCUSSION
In this study, circRERE was significantly downregulated in OA cartilage. Gain‐and loss‐of‐function experiments in vitro indicated that circRERE affected apoptosis, proliferation, and anabolic and catabolic biomarker synthesis in HCs. Furthermore, circRere overexpression in mouse knee joints reduced the severity of DMM‐induced OA by targeting the axis of miR‐195a‐5p/Irf2bpl/β‐catenin.
Importantly, we showed that the percentage of m6A‐modified circRERE was increased in OA chondrocytes, and the increased m6A level on circRERE may enhance its endoribonucleolytic cleavage by YTHDF2‐HRSP12‐RNase P/MRP. Considering that YTHDF2‐bound m6A‐modified circRNAs with HRSP‐12 binding sites (GGUUC) are preferentially degraded by RNase P/MRP, MOs‐circRERE targeting GGUUC motifs in circRERE were transfected into HCs followed by IL‐1β treatment. Decreased circRERE expression in HCs stimulated with IL‐1β for 6 h was partly reversed by MOs‐circRERE transfection, but not at 12 or 36 h, which may corroborate the preferential degradation of circRNAs in an HRSP12‐dependent manner. Functionally, the increased apoptosis of HCs upon 6 h IL‐1β stimulation was also partially rescued by MOs‐circRERE treatment.
Although the origin of increased m6A‐methylated circRERE in OA chondrocytes is unclear, it is most likely to be connected with METLL3 activity. To validate the effects of METTL3 on m6A modification of circRERE, METTL3 was silenced by siRNA in human OA chondrocytes. Unsurprisingly, METTL3 downregulation significantly decreased the m6A level on circRERE, but had no impact on the expression level of circRERE (Figure S3A‐C), indicating that METTL3 is a crucial m6A methylase for circRERE in HCs. And METTL3 activity in human chondrocytes, may at least in a significant part, be responsible for the status of m6A level on circRERE. These results suggested that METTL3 activity may be critical for cartilage homeostasis. Intriguingly, a recent report by Chen et al showed that the protein and mRNA levels of METTL3 were profoundly increased in fibroblast‐like synoviocytes (FLSs) isolated from the synovium of patients with OA compared with patients without OA, and synovium‐targeted inhibition of METTL3 alleviated the progression of OA in a DMM mouse model. 28 Thus, further trials studying the roles of m6A in the occurrence and development of OA are warranted. Notably, in our study, the reason that we use MOs‐circRERE to block two GGUUC motifs in circRERE, rather than m6A methylation sites, is though circRERE is m6A‐methylated, there are four possible m6A modification sites in circRERE. And blocking m6A sites of circRERE may influence its function of miRNA sponge.
In order to find associated pathways, we also performed KEGG analysis of differentially expressed mRNAs between the OA and control human cartilage (Figure S5I,J, the same cartilage samples used for circRNA microarray), but we did not find pathways of interest. Growing evidence highlights the need for balanced Wnt/β‐catenin signalling to maintain cartilage homeostasis. 9 , 32 Here, we showed that IRF2BPL could drive ubiquitination and degradation of β‐catenin in HCs, thus participating in the regulation of Wnt/β‐catenin signalling in HCs. In addition, WB analysis indicated that knockdown of GSK3β did not abrogate the suppressive effect of IRF2BPL on β‐catenin protein level in human chondrocytes (Figure S5R,S). Thus, IRF2BPL might degrade β‐catenin independent of GSK3β activity. IRF2BPL belongs to the IRF2BP family, which also includes IRF2BP1, IRF2BP2. And IRF2BP2 is reported to be involved in cell homeostasis regulation and promote M2 macrophage polarization, 29 and it has been reported that synovial macrophage M2 polarization slows down the progression of OA. 48 The Wnt/β‐catenin signalling is involved in various pathophysiological processes of OA, and it is interesting to note that both excessive activation and inactivation of this pathway seem to contribute to the pathogenesis of OA. 49 Thus, IRF2BPL might play a role in maintaining a fine balance of Wnt/β‐catenin signalling by driving ubiquitination and degradation of β‐catenin in HCs. Furthermore, in vitro and in vivo experiments in this study indicated the chondroprotective effects of IRF2BPL for the first time.
RIP assays showed that AGO2 was strongly bound to circRERE. Subsequent experiments in HCs showed that circRERE acted as an ceRNA to regulate target mRNA IRF2BPL and subsequent downstream target β‐catenin via sponging miR‐195‐5p. Mouse circRere expresses a homology of human circRERE (94% similarity), and the binding sequences for miR‐195‐5p in two circRNAs are conserved (Figure S4D). Furthermore, the binding of circRere to miR‐195a‐5p was also confirmed by luciferase reporter assays (Figure S4G,H). In addition, the binding sequence between miR‐195‐5p and its target IRF2BPL also shares high conservation across various vertebrates (Figure S5M). Thus, we performed DMM surgery and IA‐injection of AAVs and antagonist in mice to validate the axis of circRere/miR‐195a‐5p/Irf2bpl/β‐catenin.
Given that mass spectrometry analysis following RNA pull‐down in HCs to screen circRERE‐interacting proteins was not conducted, other proteins may interact with circRERE. Due to the existence of predicted ORFs and m6A modification in circRERE, the possibility of circRERE to encode proteins could not be excluded. Therefore, further exploration is needed to discover other possible mechanisms by which circRERE may affect the pathogenesis of OA. Another limitation of this work is that only surgically induced OA model (DMM) was examined, we did not examine other subsets of OA, such as natural age‐related OA. Follow‐up work is needed to test the function of circRERE in other subsets of OA. Furthermore, this study may be improved by employing transgenic mice with a chondrocyte‐specific promoter for circRere, rather than using AAVs to regulate circRere expression.
In conclusion, circRERE downregulation in OA chondrocytes was likely attributed to its increased m6A modification prone to endoribonucleolytic cleavage by YTHDF2‐HRSP12‐RNase P/MRP, and circRERE downregulation led to aberrant β‐catenin ubiquitination and degradation by targeting miR‐195‐5p/IRF2BPL during OA pathogenesis. Thus, concomitant targeting of m6A modification of circRERE and its downstream target miR‐195‐5p/IRF2BPL/β‐catenin might provide a synergistic effect in OA clinical treatment.
AUTHOR CONTRIBUTIONS
JL conceived this study and supervised the project. YXL conducted most of the experiments and acquired data with the help from YHY, YCL, BW, XYH, LX and WTZ. YXL and YHY contributed to data interpretation and analysis. JL wrote the manuscript. JL, YXL and YHY reviewed the manuscript. All authors approved the final manuscript.
CONFLICT OF INTEREST
The authors declare no competing interests.
Supporting information
ACKNOWLEDGEMENTS
This work was supported by grants from the National Natural Science Foundation of China (No. 82072427 and No. 81672159).
Liu Y, Yang Y, Lin Y, et al. N6 ‐methyladenosine‐modified circRNA RERE modulates osteoarthritis by regulating β‐catenin ubiquitination and degradation. Cell Prolif. 2023;56(1):e13297. doi: 10.1111/cpr.13297
Funding information National Natural Science Foundation of China, Grant/Award Numbers: 81672159, 82072427
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1. Choi WS, Lee G, Song WH, et al. The CH25H‐CYP7B1‐RORalpha axis of cholesterol metabolism regulates osteoarthritis. Nature. 2019;566(7743):254‐258. [DOI] [PubMed] [Google Scholar]
- 2. Hugle T, Geurts J. What drives osteoarthritis?‐synovial versus subchondral bone pathology. Rheumatology (Oxford). 2017;56(9):1461‐1471. [DOI] [PubMed] [Google Scholar]
- 3. Martel‐Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072. [DOI] [PubMed] [Google Scholar]
- 4. Zheng L, Zhang Z, Sheng P, Mobasheri A. The role of metabolism in chondrocyte dysfunction and the progression of osteoarthritis. Ageing Res Rev. 2021;66:101249. [DOI] [PubMed] [Google Scholar]
- 5. Rice SJ, Beier F, Young DA, Loughlin J. Interplay between genetics and epigenetics in osteoarthritis. Nat Rev Rheumatol. 2020;16(5):268‐281. [DOI] [PubMed] [Google Scholar]
- 6. Coryell PR, Diekman BO, Loeser RF. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat Rev Rheumatol. 2021;17(1):47‐57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Berenbaum F, Wallace IJ, Lieberman DE, Felson DT. Modern‐day environmental factors in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2018;14(11):674‐681. [DOI] [PubMed] [Google Scholar]
- 8. Hunter DJ, Bierma‐Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745‐1759. [DOI] [PubMed] [Google Scholar]
- 9. Latourte A, Kloppenburg M, Richette P. Emerging pharmaceutical therapies for osteoarthritis. Nat Rev Rheumatol. 2020;16(12):673‐688. [DOI] [PubMed] [Google Scholar]
- 10. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115‐2126. [DOI] [PubMed] [Google Scholar]
- 11. Emery CA, Whittaker JL, Mahmoudian A, et al. Establishing outcome measures in early knee osteoarthritis. Nat Rev Rheumatol. 2019;15(7):438‐448. [DOI] [PubMed] [Google Scholar]
- 12. Berenbaum F, Meng QJ. The brain‐joint axis in osteoarthritis: nerves, circadian clocks and beyond. Nat Rev Rheumatol. 2016;12(9):508‐516. [DOI] [PubMed] [Google Scholar]
- 13. Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675‐691. [DOI] [PubMed] [Google Scholar]
- 14. Shen S, Yang Y, Shen P, et al. circPDE4B prevents articular cartilage degeneration and promotes repair by acting as a scaffold for RIC8A and MID1. Ann Rheum Dis. 2021;80:1209‐1219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Yang Y, Shen P, Yao T, et al. Novel role of circRSU1 in the progression of osteoarthritis by adjusting oxidative stress. Theranostics. 2021;11(4):1877‐1900. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Yang L, Han B, Zhang Z, et al. Extracellular vesicle‐mediated delivery of circular RNA SCMH1 promotes functional recovery in rodent and nonhuman primate ischemic stroke models. Circulation. 2020;142(6):556‐574. [DOI] [PubMed] [Google Scholar]
- 17. Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m(6)a RNA methylation. Nat Rev Genet. 2014;15(5):293‐306. [DOI] [PubMed] [Google Scholar]
- 18. Huang H, Weng H, Sun W, et al. Recognition of RNA N(6)‐methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285‐295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Zhang S, Zhao BS, Zhou A, et al. M(6)a demethylase ALKBH5 maintains Tumorigenicity of glioblastoma stem‐like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31(4):591‐606. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6‐methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Di Timoteo G, Dattilo D, Centron‐Broco A, et al. Modulation of circRNA metabolism by m(6)a modification. Cell Rep. 2020;31(6):107641. [DOI] [PubMed] [Google Scholar]
- 22. Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6‐methyladenosine in cancer progression. Mol Cancer. 2020;19(1):88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Engel M, Eggert C, Kaplick PM, et al. The role of m(6)a/m‐RNA methylation in stress response regulation. Neuron. 2018;99(2):389‐403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Berulava T, Buchholz E, Elerdashvili V, et al. Changes in m6A RNA methylation contribute to heart failure progression by modulating translation. Eur J Heart Fail. 2020;22(1):54‐66. [DOI] [PubMed] [Google Scholar]
- 25. Yang Y, Shen F, Huang W, et al. Glucose is involved in the dynamic regulation of m6A in patients with type 2 diabetes. J Clin Endocrinol Metab. 2019;104(3):665‐673. [DOI] [PubMed] [Google Scholar]
- 26. Park OH, Ha H, Lee Y, et al. Endoribonucleolytic cleavage of m(6)A‐containing RNAs by RNase P/MRP complex. Mol Cell. 2019;74(3):494‐507 e498. [DOI] [PubMed] [Google Scholar]
- 27. Liu Q, Li M, Jiang L, Jiang R, Fu B. METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019;516(1):22‐27. [DOI] [PubMed] [Google Scholar]
- 28. Chen X, Gong W, Shao X, et al. METTL3‐mediated m(6)a modification of ATG7 regulates autophagy‐GATA4 axis to promote cellular senescence and osteoarthritis progression. Ann Rheum Dis. 2021;81(1):85‐97. [DOI] [PubMed] [Google Scholar]
- 29. Ramalho‐Oliveira R, Oliveira‐Vieira B, Viola JPB. IRF2BP2: a new player in the regulation of cell homeostasis. J Leukoc Biol. 2019;106(3):717‐723. [DOI] [PubMed] [Google Scholar]
- 30. Higashimori A, Dong Y, Zhang Y, et al. Forkhead box F2 suppresses gastric cancer through a novel FOXF2‐IRF2BPL‐beta‐catenin signaling Axis. Cancer Res. 2018;78(7):1643‐1656. [DOI] [PubMed] [Google Scholar]
- 31. Bertrand J, Kraft T, Gronau T, et al. BCP crystals promote chondrocyte hypertrophic differentiation in OA cartilage by sequestering Wnt3a. Ann Rheum Dis. 2020;79(7):975‐984. [DOI] [PubMed] [Google Scholar]
- 32. Lietman C, Wu B, Lechner S, et al. Inhibition of Wnt/beta‐catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI . Insight. 2018;3(3):e96308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Bi W, Huang J, Nie C, et al. CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1‐dependent activation of beta‐catenin pathway. J Exp Clin Cancer Res. 2018;37(1):275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Huang G, Liang M, Liu H, et al. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR‐187‐3p/RTKN2 axis and activating Wnt/beta‐catenin pathway. Cell Death Dis. 2020;11(12):1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Liu M, Wang Q, Shen J, Yang BB, Ding X. Circbank: a comprehensive database for circRNA with standard nomenclature. RNA Biol. 2019;16(7):899‐905. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Huang J, Zhao L, Fan Y, et al. The microRNAs miR‐204 and miR‐211 maintain joint homeostasis and protect against osteoarthritis progression. Nat Commun. 2019;10(1):2876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Zhao L, Huang J, Fan Y, et al. Exploration of CRISPR/Cas9‐based gene editing as therapy for osteoarthritis. Ann Rheum Dis. 2019;78(5):676‐682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Zhang L, Hou C, Chen C, et al. The role of N(6)‐methyladenosine (m(6)a) modification in the regulation of circRNAs. Mol Cancer. 2020;19(1):105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Ma S, Chen C, Ji X, et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol. 2019;12(1):121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Xu J, Ji L, Liang Y, et al. CircRNA‐SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020;5(1):298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Xu J, Wan Z, Tang M, et al. N(6)‐methyladenosine‐modified CircRNA‐SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating beta‐catenin signaling. Mol Cancer. 2020;19(1):163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Garikipati VNS, Verma SK, Cheng Z, et al. Circular RNA CircFndc3b modulates cardiac repair after myocardial infarction via FUS/VEGF‐A axis. Nat Commun. 2019;10(1):4317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34‐42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384‐388. [DOI] [PubMed] [Google Scholar]
- 45. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR‐7 in cancer. Cancer Res. 2013;73(18):5609‐5612. [DOI] [PubMed] [Google Scholar]
- 46. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333‐338. [DOI] [PubMed] [Google Scholar]
- 47. Li K, Zhang Y, Zhang Y, et al. Tyrosine kinase Fyn promotes osteoarthritis by activating the beta‐catenin pathway. Ann Rheum Dis. 2018;77(6):935‐943. [DOI] [PubMed] [Google Scholar]
- 48. Zhang H, Lin C, Zeng C, et al. Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R‐spondin‐2. Ann Rheum Dis. 2018;77(10):1524‐1534. [DOI] [PubMed] [Google Scholar]
- 49. Shang X, Boker KO, Taheri S, Hawellek T, Lehmann W, Schilling AF. The interaction between microRNAs and the Wnt/beta‐catenin signaling pathway in osteoarthritis. Int J Mol Sci. 2021;22(18):9887. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.